Itvisma (onasemnogene abeparvovec-brve)
An approved treatment for Spinal Muscular Atrophy.
Drug facts
The same compound appears under different names depending on the context. Here is how to identify Onasemnogene abeparvovec-brve wherever you encounter it, plus the key facts at a glance.
- Generic name
- Onasemnogene abeparvovec-brve
- Brand name
- Itvisma
- Development codes
- OAV101 IT, AVXS-101 IT
- Drug class
- Gene therapy (intrathecal)
- Manufacturer
- Novartis Gene Therapies
- How it's taken
- Given as a single one-time intrathecal injection (lumbar puncture) at a specialized treatment center.
An intrathecal gene replacement therapy for spinal muscular atrophy (SMA) approved for patients 2 years and older with a confirmed SMN1 gene mutation.
Itvisma is the same AAV9 vector platform as Zolgensma but delivered directly into the spinal fluid rather than the bloodstream, making it the first gene replacement therapy available to older children, teens, and adults with SMA.
We'll email you when Itvisma's FDA label changes, when the FDA acts on it, and when new trials for Spinal Muscular Atrophy open. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Where Onasemnogene abeparvovec-brve fits
First and only gene replacement therapy approved for SMA patients 2 years and older.
- Fills the major gap left by Zolgensma, which is generally restricted to younger children and weight-based dosing.
- For older patients previously limited to chronic therapies (nusinersen or risdiplam), Itvisma offers a one-time treatment option.
How Onasemnogene abeparvovec-brve works
Itvisma uses a harmless adeno-associated virus 9 (AAV9) vector to deliver a working copy of the SMN1 gene directly to motor neurons in the spinal cord. In SMA, the SMN1 gene is missing or non-functional, so motor neurons gradually die.
By delivering the replacement gene intrathecally (directly into the spinal fluid), Itvisma concentrates the therapy where it is needed most. The single dose is fixed and does not need to be adjusted for age or body weight, which is what makes treatment feasible in older, larger patients.
Side effects and safety
The most common side effects in trials were upper respiratory infections, upper stomach symptoms such as vomiting, fever, and headache. The label also warns about nerve damage causing numbness, tingling or pain in the hands and feet (starting about 3 weeks after treatment), thrombotic microangiopathy (a dangerous clotting problem), and raised troponin (a heart marker).
Itvisma has a boxed warning (the FDA's strongest warning) for serious liver injury, so liver function is checked before treatment and for at least 3 months after, and corticosteroids are given before and after the injection. It can also lower platelet counts (thrombocytopenia), so platelets are checked before treatment and at least weekly for the first month.
The label also notes a theoretical risk of tumors from the gene therapy. On November 6, 2026 the FDA said this tumor risk applies to Itvisma as well as Zolgensma, since both contain the same vector and gene construct, after confirmed reports of tumors caused by Zolgensma's DNA inserting next to or inside a cancer-causing gene [1]. No tumors had been reported after Itvisma as of that notice, and the FDA says people treated should be monitored for tumors. Patients should be tested for anti-AAV9 antibodies before treatment.
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking Onasemnogene abeparvovec-brve
Given as a single one-time intrathecal injection (lumbar puncture) at a specialized treatment center. Patients receive corticosteroids before and after the procedure to manage immune response. Unlike weight-based IV Zolgensma, Itvisma uses a fixed dose, allowing it to be given to older children, teens, and adults regardless of size.
Availability and cost
Only available as the brand-name product.
One-time AAV9 intrathecal gene therapy. Pricing reflects the same complex viral vector manufacturing as Zolgensma plus the surgical/intrathecal administration overhead, in a curative-intent single-dose model.
Help paying for Itvisma
With private insurance, the drugmaker's copay card can lower what you pay for Itvisma. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. Of the 4 charity funds for Spinal Muscular Atrophy, 2 were open on October 26, 2026. Pick your insurance below to see which offers fit you.
- Insurance and case manager help
A dedicated Case Coordinator helps with benefits verification, prior authorization, appeals, financial support options, and tracking treatment delivery.
The official page does not say who qualifies. Ask the program. · source - Copay help
ZOLGENSMA and ITVISMA CopayAssist Program helps reduce out-of-pocket costs for eligible patients with private insurance.
For: private insurance · source - Free medicine program
The Novartis Patient Assistance Program for ITVISMA is available for eligible people with SMA and families; contact Novartis Patient Support.
The official page does not say who qualifies. Ask the program. · source
Good to know: Enrollment requires a signed Novartis Patient Support Start Form. Eligibility rules for the patient assistance program and copay limits are not stated on the official page.
Charity funds for Spinal Muscular Atrophy
- From a charity · Cure SMATravel Support Package fundOpen
Pays for: A package of travel equipment, such as a portable transfer sling, to help adults with SMA fly more safely.
The foundation says: “Cure SMA says the travel support package is currently available to adults with SMA who live in the U.S. The equipment loan pool is no lon…” - From a charity · TotalAssist (formerly PAN Foundation)Spinal Muscular Atrophy fundOpen
Pays for: Out-of-pocket costs for approved medications, up to $6,500 per year. Requires health insurance (any kind).
- From a charity · Muscular Dystrophy AssociationMDA Durable Medical Equipment (DME) Grant Program fundApply directly
Pays for: Medical equipment (wheelchairs, lifts, canes and other DME), up to $1,000 per year.
The foundation says: “Status not shown on page”
Every program and charity fund for Spinal Muscular Atrophy →
Access and eligibility
Indicated for adults and children 2 years and older with SMA and a confirmed mutation in the SMN1 gene. Patients who were previously treated with Zolgensma should not receive Itvisma. Anti-AAV9 antibodies are tested before treatment, and the clinical trials only enrolled patients with low antibody levels (1:50 or below).
Source: Novartis (Itvisma approval announcement)
Access program details are provided for informational purposes and may vary based on insurance coverage, geographic location, and individual circumstances. Confirm current eligibility directly with the manufacturer or your specialty pharmacy.
Clinical trial results
FDA approval (November 24, 2025) was based on the Phase 3 STEER study and supportive findings from the ongoing Phase 3b STRENGTH study. STEER showed a statistically significant improvement in the Hammersmith Functional Motor Scale Expanded (HFMSE): scores rose 2.39 points with Itvisma and 0.51 points with a sham procedure, a difference of 1.88 points, in treatment-naive SMA patients 2-17 years old.
Development history
Developed by Novartis Gene Therapies as the intrathecal counterpart to Zolgensma. Although both products use the same AAV9 vector and the same transgene, FDA approval was sought separately for the intrathecal route given the different administration method, dosing, and patient population. Approved November 24, 2025 as the first gene replacement therapy available for SMA patients age 2 and older, including teens and adults.
Explore Spinal Muscular Atrophy trials
Other Spinal Muscular Atrophy treatments
Common questions about Onasemnogene abeparvovec-brve
▸What is Onasemnogene abeparvovec-brve (Itvisma)?
An intrathecal gene replacement therapy for spinal muscular atrophy (SMA) approved for patients 2 years and older with a confirmed SMN1 gene mutation. Itvisma is the same AAV9 vector platform as Zolgensma but delivered directly into the spinal fluid rather than the bloodstream, making it the first gene replacement therapy available to older children, teens, and adults with SMA.
▸How does Onasemnogene abeparvovec-brve work?
Itvisma uses a harmless adeno-associated virus 9 (AAV9) vector to deliver a working copy of the SMN1 gene directly to motor neurons in the spinal cord. In SMA, the SMN1 gene is missing or non-functional, so motor neurons gradually die.
By delivering the replacement gene intrathecally (directly into the spinal fluid), Itvisma concentrates the therapy where it is needed most. The single dose is fixed and does not need to be adjusted for age or body weight, which is what makes treatment feasible in older, larger patients.
▸What are the side effects of Onasemnogene abeparvovec-brve?
The most common side effects in trials were upper respiratory infections, upper stomach symptoms such as vomiting, fever, and headache. The label also warns about nerve damage causing numbness, tingling or pain in the hands and feet (starting about 3 weeks after treatment), thrombotic microangiopathy (a dangerous clotting problem), and raised troponin (a heart marker). Itvisma has a boxed warning (the FDA's strongest warning) for serious liver injury, so liver function is checked before treatment and for at least 3 months after, and corticosteroids are given before and after the injection. It can also lower platelet counts (thrombocytopenia), so platelets are checked before treatment and at least weekly for the first month. The label also notes a theoretical risk of tumors from the gene therapy. On November 6, 2026 the FDA said this tumor risk applies to Itvisma as well as Zolgensma, since both contain the same vector and gene construct, after confirmed reports of tumors caused by Zolgensma's DNA inserting next to or inside a cancer-causing gene [1]. No tumors had been reported after Itvisma as of that notice, and the FDA says people treated should be monitored for tumors. Patients should be tested for anti-AAV9 antibodies before treatment.
▸How is Onasemnogene abeparvovec-brve taken?
Given as a single one-time intrathecal injection (lumbar puncture) at a specialized treatment center. Patients receive corticosteroids before and after the procedure to manage immune response. Unlike weight-based IV Zolgensma, Itvisma uses a fixed dose, allowing it to be given to older children, teens, and adults regardless of size.
▸Is Onasemnogene abeparvovec-brve FDA approved?
Yes, Onasemnogene abeparvovec-brve (Itvisma) is FDA approved (2025) for the treatment of Spinal Muscular Atrophy.
▸How does intrathecal Zolgensma differ from the IV version?
Itvisma is injected once into the spinal fluid at the same fixed dose for every patient aged 2 and older. IV Zolgensma goes into a vein at a dose set by body weight and is approved for children under 2.
▸Who is eligible for intrathecal Zolgensma?
Intrathecal onasemnogene-abeparvovec-brve is approved for SMA patients aged 2 years and older. It fills the age gap for patients too old for IV Zolgensma, providing a gene therapy option across the lifespan.
▸When was this version approved?
The intrathecal formulation was approved in 2025, expanding the gene therapy option beyond the under-2 age group covered by the original IV Zolgensma approved in 2019.
▸Is this also a one-time treatment?
Yes. Like the IV version, intrathecal Zolgensma is a one-time treatment aimed at providing sustained SMN protein production. The intrathecal delivery targets the central nervous system directly.
▸What monitoring is required after treatment?
Similar to IV Zolgensma, liver function monitoring, corticosteroid management, and regular follow-up are required after intrathecal administration. Specific monitoring protocols may differ based on the delivery route.
▸Were adults included in the Itvisma trials?
No. The STEER and STRENGTH trials enrolled people aged 2 to 17, and the FDA extended the approval to adults based on the company's justification. STREAM (NCT07448610), a Novartis study that began on August 27, 2026, is collecting Itvisma data in adults during routine US care. Trial Friend's guide to Itvisma for adults with SMA covers the details.
▸Do insurers cover Itvisma for adults?
It depends on the insurer. Of 5 published policies Trial Friend read on October 24, 2026, Aetna and Cigna cover Itvisma only from age 2 through 17, while UnitedHealthcare, Anthem and the Blue Cross Blue Shield Federal Employee Program set no upper age. Your plan's written policy decides.
▸Does the Zolgensma tumor risk apply to Itvisma?
Yes. The FDA said on November 6, 2026 that the tumor risk found with Zolgensma applies to Itvisma too, because the 2 products contain the same vector and gene construct.
Itvisma so far: No tumors had been reported after Itvisma as of the FDA's notice. Itvisma was approved on November 24, 2025.
Zolgensma cases: Reports after approval include tumors of the brain and spinal cord, the nerves, the area along the spine and the kidney. In 2 cases tied to a cancer-causing gene called GLI1, testing found Zolgensma's DNA inserted next to or inside that gene.
FDA view: The FDA says the benefits still outweigh the potential risks for the approved uses, while it decides whether the label or other action should change.
Monitoring: The FDA says people treated should be monitored for tumors. A care team can explain what that monitoring includes.
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- U.S. Food and Drug Administration · 2026-11-06. FDA Investigating Serious Risk of Malignancy Linked to Zolgensma Gene Therapy. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-malignancy-linked-zolgensma-gene-therapy
- U.S. National Library of Medicine, DailyMed. ITVISMA (onasemnogene abeparvovec-brve) prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab2e1c6c-4f95-4243-9296-1734e0a30591